Financial reports
10-K
2023 FY
Annual report
19 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
17 Mar 22
Current reports
8-K
Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
18 Mar 24
8-K
Unregistered Sales of Equity Securities
7 Feb 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
8-K
Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie
21 Dec 23
8-K
Alpine Immune Sciences Reports Third Quarter 2023 Financial Results
14 Nov 23
8-K
Entry into a Material Definitive Agreement
7 Nov 23
8-K
Results of Operations and Financial Condition
6 Nov 23
8-K
Other Events
2 Nov 23
8-K
Alpine Immune Sciences Reports Second Quarter 2023 Financial Results
14 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
20 Mar 24
S-8
Registration of securities for employees
20 Mar 24
424B5
Prospectus supplement for primary offering
7 Nov 23
FWP
Free writing prospectus
6 Nov 23
424B5
Prospectus supplement for primary offering
6 Nov 23
POS AM
Prospectus update (post-effective amendment)
14 Aug 23
424B5
Prospectus supplement for primary offering
11 May 23
S-3
Shelf registration
28 Apr 23
S-8
Registration of securities for employees
23 Mar 23
S-8
Registration of securities for employees
23 Mar 23
Proxies
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
DEFA14A
Additional proxy soliciting materials
5 May 20
DEF 14A
Definitive proxy
5 May 20
DEFA14A
Additional proxy soliciting materials
24 Apr 19
Other
EFFECT
Notice of effectiveness
17 Aug 23
EFFECT
Notice of effectiveness
10 May 23
CORRESP
Correspondence with SEC
5 May 23
UPLOAD
Letter from SEC
5 May 23
CT ORDER
Confidential treatment order
23 Mar 22
CT ORDER
Confidential treatment order
23 Mar 22
EFFECT
Notice of effectiveness
22 Nov 21
CORRESP
Correspondence with SEC
17 Nov 21
UPLOAD
Letter from SEC
16 Nov 21
UPLOAD
Letter from SEC
7 Oct 21
Ownership
SC 13G/A
BlackRock Inc.
7 Mar 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
Omega Fund VI, L.P.
14 Feb 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
Paradigm Biocapital Advisors LP
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
Lynx1 Capital Management LP
14 Feb 24
SC 13G
BlackRock Inc.
2 Feb 24
4
James Paul Rickey
29 Jan 24
144
Notice of proposed sale of securities
26 Jan 24